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Abstract: Aristolochic acid (AA) is a plant alkaloid that causes aristolochic acid nephropathy (AAN)
and Balkan endemic nephropathy (BEN), unique renal diseases frequently associated with upper
urothelial cancer (UUC). This review summarizes the significance of AA-derived DNA adducts in
the aetiology of UUC leading to specific A:T to T:A transversion mutations (mutational signature) in
AAN/BEN-associated tumours, which are otherwise rare in individuals with UCC not exposed to
AA. Therefore, such DNA damage produced by AA-DNA adducts is one rare example of the direct
association of exposure and cancer development (UUC) in humans, confirming that the covalent
binding of carcinogens to DNA is causally related to tumourigenesis. Although aristolochic acid
I (AAI), the major component of the natural plant extract AA, might directly cause interstitial
nephropathy, enzymatic activation of AAI to reactive intermediates capable of binding to DNA
is a necessary step leading to the formation of AA-DNA adducts and subsequently AA-induced
malignant transformation. Therefore, AA-DNA adducts can not only be utilized as biomarkers for the
assessment of AA exposure and markers of AA-induced UUC, but also be used for the mechanistic
evaluation of its enzymatic activation and detoxification. Differences in AA metabolism might be one
of the reasons for an individual’s susceptibility in the multi-step process of AA carcinogenesis and
studying associations between activities and/or polymorphisms of the enzymes metabolising AA is
an important determinant to identify individuals having a high risk of developing AA-mediated UUC.
Keywords: aristolochic acid; carcinogenicity; mutagenesis; nephrotoxicity; DNA adduct formation
1. Introduction
Human exposures to chemicals with carcinogenic potency are considered to be connected with
cancer development, predominantly when such exposures are frequent and long-term [1–3]. Several
reviews conducted by Poirier [1–3] provided an overview on the carcinogenic nature of specific
exposures to chemicals such as polycyclic aromatic hydrocarbons (PAHs) and aromatic amines which
are considered to be associated with cancers in the human population for centuries. The carcinogenicity
of these chemicals was also determined in studies employing animal models (for a review see [2,4].
The formation of covalent DNA adducts by carcinogens is considered to be one of the earliest steps
in the initiation phase of cancer development [5,6]. The formation of these DNA adducts is dependent
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on the type of DNA bases and is influenced by the DNA sequence context. DNA adducts can be
repaired at different rates depending on the fact whether they are located or not on the transcribed
or non-transcribed strand of DNA, in addition to the phenomenon which nucleotide sequences
is modified [7,8]. Some highly reactive genotoxic carcinogens are capable of directly interacting
with DNA (e.g., alkylating agents) but most of them (e.g., many PAHs [9] or heterocyclic aromatic
amines (HAAs) [10]) are chemically inert and require metabolic conversion before exerting their
genotoxic properties [3,10–13]. The covalent binding of carcinogens to DNA, which is causally related
to tumorigenesis, is now considered as a central dogma of chemical carcinogenesis. This belief
is supported by various observations, such as the facts that: (i) the carcinogenic properties of
many carcinogens is, as mentioned above, dependent upon their activation to reactive electrophilic
derivatives, which react with nucleophilic sites within DNA; (ii) the extent of DNA adduct formation
can often be correlated with the magnitude of carcinogenic responses; and (iii) mutations in certain
tumor suppressor genes and the activation of several proto-oncogenes can be mediated by the
interaction of carcinogens with DNA.
However, since humans are exposed not only to one but to a complex mixture of carcinogens,
direct proofs of an association of exposure to the development of a specific cancer type are rare.
The plant carcinogen aristolochic acid (AA) and the mycotoxin aflatoxin B1 [14,15] are two rare
examples where a distinct environmental exposure is linked to tumour development in humans.
This review focuses on AA and the significance of AA-specific DNA adducts as biomarkers of
AA exposure and markers for the development of upper urothelial cancer (UUC) in AA-exposed
individuals. The review also focuses on the mechanisms of AA enzymatic activation and detoxification
which are critical determinants for AA-induced UUC development.
2. Aristolochic Acid
AA, the extract of plants of the Aristolochiaceae family, is a mixture of structurally
related nitrophenanthrene carboxylic acids, with two major components: aristolochic acid I
(8-methoxy-6-nitro-phenanthro-(3,4-d)-1,3-dioxolo-5-carboxylic acid, AAI) and aristolochic acid II
(6-nitro-phenanthro-(3,4-d)-1,3-dioxolo-5-carboxylic acid, AAII) (Figure 1). AA is present particularly
in plants of the Aristolochia and Asarum genera of the family Aristolochiaceae, in all plant parts.
Aristolochia plants have been used for herbal medicinal remedies throughout the world since antiquity
and they remain in use today, particularly in Chinese herbal medicine [16–24]. Both AAI and AAII are
mutagenic and genotoxic [16,25–28] forming covalent DNA adducts after reductive activation in vitro
and in vivo (reviewed in [16–24]).
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2.1. Aristolochic Acid ( A) as a Carcinogen Causing Upper Urothelial Cancer in Aristolochic Acid
Nephropathy (AAN) and Balkan Endemic Nephropathy (BEN) Patients and Renal Cell Carcinoma in
Certain Other Human Populations
In 2012 A was classified as carcinogenic to humans (Group 1) by the International Agency
for Research on Cancer (IARC) acting by a genotoxic mechanism [29]. Today there is compelling
evidence that hu an exposure to A leads to UUC in patients with renal disease which is now termed
aristolochic acid nephropathy (AAN) [29,30]. This disease is now recognized as a global disease; in
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Europe AAN has been found in Belgium, UK, France, Croatia, Serbia and Romania, in Asia in China
and Taiwan [16–18,21,23,24,27,31–33].
The occurrence of this renal disease was first described by Vanherweghem et al. [33] and initially
termed Chinese herbs nephropathy (CHN). Vanherweghem et al. [33] found this disease in young
Belgian women treated with a sliming regimen in one clinic in Brussels. It was subsequently
demonstrated that the pills used in the slimming regimen contained Chinese herbs that were
contaminated with the nephrotoxin AA. Its presence in the slimming pills was the result of an
accidental substitution of the prescribed herb Stephania tetrandra by Aristolochia fangchi, a plant species
of the Aristolochia genus known to contain AA. Because AA was found to be the cause of this disease, it
was later renamed as AAN [34,35]. Only a few years after the first description of AAN, UCC developed
in almost 50% of these patients [27,36,37]. Recent studies indicated linking AA not only to upper
urothelial cancers, but also renal cell carcinoma (RCC) [31] and to liver premalignant alterations [38,39].
AA is also considered as the major cause of another chronic renal disease associated with urothelial
malignancy named Balkan endemic nephrophathy (BEN) [17,18,21–24,30,40]. It is believed that dietary
contamination in endemic areas by Aristolochia clematitis seeds was the reason for AA exposure and
subsequently the development of BEN. Indeed, a recent study showed that AAs could be released
from the decay of Aristolochia plant growing abundantly as weeds in farmland in endemic areas of the
Balkan Peninsula subsequently taken up by food crops from the polluted soil and contaminated the
food grains [41].
2.1.1. AA-Derived DNA Adducts and Their Role in the Initiation of Upper Urothelial Cancer
AAI and AAII are both enzymatically reduced to reactive cyclic acylnitrenium ions that can bind to
the exocyclic amino groups of dA, dG and dC, forming covalent DNA adducts. In humans, specifically
7-(deoxyadenosin-N6-yl)aristolactam I or II (dA-AAI or dA-AAII) and 7-(deoxyguanosin-N2-yl)aristolactam
I or II (dG-AAI or dG-AAII) have been identified (Figure 2) [17,18,42–47].
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Figure 2. Reductive activation of aristolochic acid I [8-methoxy-6-nitro-phenanthro-(3,4-d)-1,3-dioxolo-
5-carboxylic acid, AAI; R = OCH3] and II [6-nitro-phenanthro-(3,4-d)-1,3-dioxolo-5-carboxylic acid,
AAII; R = H] leading to formation of DNA adducts. 7-(deoxyadenosin-N6-yl)aristolactam I or
II (dA-AAI or dA-AAII), 7-(deoxyguanosin-N2-yl)aristolactam I or II (dG-AAI or dG-AAII). ?,
possible pathway.
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Specific AA-derived DNA adducts in renal and ureteric tissue of CHN/AAN patients were
first determined by Schmeiser and coworkers [27,34,44,48,49], unequally proving exposure to AA in
these patients. Furthermore, the detection of a specific AAG to TAG transversion mutation (an A:T
to T:A transversion mutation) in the tumour suppressor gene TP53 in one patient suffering from
AAN-associated urothelial cancer [50] in combination with a high prevalence of A:T to T:A transversion
mutations found in transgenic rodent mutation assays after AA exposure (reviewed in [50]) set the
stage that this mutation pattern is now recognised as the mutational signature of AA and is used
as another indicator for AA exposure [32,50]. Such A:T to T:A transversion mutations were later
also confirmed in a larger group of CHN/AAN patients suffering from urothelial malignancy [51,52].
However, other types of mutations were also found in the tumours of these patients. The selectivity for
mutations at adenine residues in AA-induced urothelial tumours corresponds to the high prevalence
of dA-AAI adducts in the target tissue of CHN/AAN patients. This adduct exhibits a long persistence
in renal tissue and is still detectable in CHN/AAN patients decades after AA exposure [53]. It was
shown that mutated adenine found in TP53 (i.e., codon 139) [49] has the same neighboring bases
as in codon 61 (CAA) of the H-ras proto-oncogene in experimental animals (rats, mice). In these
experimentally-induced tumours specific A:T to T:A transversions were also identified after AA
treatment suggesting a sequence-specific mechanism during mutation induction [54–58]. Since the A:T
to T:A transversions found in TP53 correspond to the mutagenic specificity known for AA [54–58], it
was proposed that these AA-induced transversion mutations in the TP53 gene of urothelial tumours
could be utilised as mechanistically relevant biomarkers of AA exposure in combination with specific
AA-DNA adducts found in renal tissue of AAN patients [49,50]. This suggestion seems to be reasonable,
because TP53 mutations at these sites have not previously been associated with UUC and seem to be
uniquely associated with exposure to AA [50,59,60]. Moreover, these findings explained the molecular
mechanism, whereby AA causes urothelial malignancy [23,50].
The data showing that dA-AAI is the most abundant and persistent DNA adduct found in patients
suffering from CHN/AAN [16,27,44,53,61,62] indicated that this adduct is an robust biomarker of
AA exposure in patients suffering from this disease or in other individuals exposed to AA. AA-DNA
adducts were also used as biomarkers of exposure in BEN patients. Exposure to AA in patients with
renal disease living in areas endemic for BEN was first demonstrated by Arlt and collaborators [63]
suggesting that AA is a causal factor in the development of BEN. Subsequently AA-DNA adducts
in kidney tissue were proven in larger cohorts of patients with definite diagnosis of BEN, living in
endemic regions in Croatia, Serbia, Bosnia and Romania [30,64,65]. Of note, no such AA-DNA adducts
were identified in patients with other forms of chronic renal disease or patients with UCC living in
non-endemic areas of Croatia and Serbia [64,65]. Similarly, Schmeiser and coworkers [30] determined
AA-DNA adducts (i.e., dA-AAI) in kidney tissue of patients who underwent nephroureterectomy
because of UUC and resided for 17 years or longer in villages of BEN areas in Romania. These results
emphasise the significance of these DNA adducts and demonstrate their direct connections with AA
exposures and with development of UUC in humans.
One important conclusion of all studies in CHN/AAN and BEN patients is that both diseases are
preventable with simple control measures. Specifically, both diseases could be completely eliminated
with a stronger regulation of herbal medicines and the prevention of dietary exposure to AA [23]. Even
though herbal remedies containing AA have been banned in many countries, the risk of AA exposure
caused by botanicals remains high in many regions of the world [23]. As a consequence, AAN can
be considered, as it was postulated by Grollman [24], a global iatrogenic disease. From this point of
view, an important advance in the ability to analyse AA-derived DNA adducts was recently achieved,
because mass spectrometry has been proven to be a highly sensitive, specific and robust analytical
method capable of identifying these adducts [53,66–71]. Mass spectrometry can therefore serve as
an alternative to the 32P-postlabelling technique [64], the method which has been widely utilised
over the last decades to detect and quantify AA-DNA adducts in human biomonitoring. Namely,
mass spectrometry is able to identify the structure of the DNA adduct. The successful utilization of
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this approach was shown by analysing kidney tissue from Romanian cancer patients. RCC has not
been reported in CHN/AAN patients previously but some Romanian patients unexpectedly showed
high frequencies of A:T to T:A transversion mutations by whole-genome sequencing of the renal
tumours, which is consistent with AA exposure [70]. A subsequent study utilised mass spectrometry
and dA-AAI adducts were found in these Romanian cases unequivocally demonstrating exposure to
AA in these patients [71]. As these patients do not cover the Romanian population of the BEN area [65],
the source of AA exposure has not yet been identified in this cohort. Nevertheless, utilising AA-DNA
adducts as biomarker of exposure and the unique mutational signature of AA as biomarker of effect
clearly identified AA as an aetiologic agent of renal cell carcinoma seen in these patients. Indeed,
recently Hoang et al. [31] also detected AA-derived DNA adducts in the kidneys of Taiwanese patients
suffering from renal cell carcinoma providing additional evidence that AA not only causes UUC but
also RCC.
The detection of AA-DNA adducts (i.e., dA-AAI) in the renal tissue of human individuals exposed
to AA in several countries over the world is summarised in Table 1.
Besides demonstrating AA exposure by the detection of specific AA-DNA adducts, other
approaches used the detection of A:T to T:A mutations in TP53 as a marker of AA-induced cancer risk
in Taiwan [72,73]. This study confirmed the hypothesis that the mutational signature of AA in the TP53
gene found in UUC-associated with CHN/AAN or BEN [59,64], is the same as that determined in
Taiwanese patients with UUC [72]. More recently, characteristic A:T to T:A transversion mutations were
also found in loci of other genes by whole-genome and exome sequencing analysing AA-associated
UUC [74,75] illustrating that next-generation sequencing provides a powerful approach to study AA
exposure in cohorts or cancers not yet linked to AA.
The A:T to T:A transversions produced after AA exposure are almost exclusively located on the
non-transcribed strand of DNA [76] suggesting that this marked strand bias might be linked to the
slow removal of dA-AAI adducts from the transcribed strand by transcription-coupled nucleotide
excision repair [59,76,77]. Resistance of dA-AAI adducts to global genomic repair may reflect the
inability of XPC-RAD23B to recognise and bind to these lesions in duplex DNA [76]. This failure of
global genomic repair to excise AA-derived DNA adducts may also account for the persistence of these
lesions in human tissues [24]. Indeed this conclusion is in accordance with the detection of AA-DNA
adducts (i.e., dA-AAI) in CHN/AAN patients even decades after exposure to AA [53].
All these studies summarised above provided important advances in explaining the molecular
mechanism of AA-induced carcinogenesis. As a result, the National Toxicology Program (NTP) [78]
lists AA as carcinogenic to humans. The NTP report postulated that “sufficient” scientific evidence is
available to conclude that exposure to AA causes urothelial cancer in humans through formation of
DNA adducts (specifically, through binding of the reactive metabolite with adenine) and the resulting
transversion mutations in oncogenes and the tumour suppressor gene TP53. Likewise, AA was
classified as human carcinogen (Group 1) by the IARC acting by a genotoxic mechanism [29].
Int. J. Mol. Sci. 2017, 18, 2144 6 of 19
Table 1. DNA adduct levels (dA-AAI) in human renal tissue from individuals exposed to AA.
Country DNA Adduct Measured in DNA Adduct Detected DNA Adduct Level/108 Nucleotides Method Used for DNA Adduct Detection Publication Year Reference
Belgium Kidney dA-AAI 7.0–53.0 (n = 6) TLC 1 32P-postlabelling 1996, 1997 [44,62]
Belgium Kidney dA-AAI 0.1–16.5 (n = 38) TLC 32P-postlabelling 2000 [27]
Belgium Kidney dA-AAI 2.9–5.0 (n = 2) TLC 32P-postlabelling 2001 [61]
Belgium/China Kidney dA-AAI 1.8 (n = 1) TLC 32P-postlabelling 2001 [79]
UK Kidney dA-AAI 3.8 (n = 1) TLC 32P-postlabelling 2001, 2004 [48,49]
Croatia Kidney dA-AAI 0.56–1.71 (n = 2) TLC 32P-postlabelling 2002 [63]
Belgium Kidney dA-AAI 8.1 (n = 1) TLC 32P-postlabelling 2003 [80]
France Kidney dA-AAI 0.1–5.4 (n = 2) TLC 32P-postlabelling 2004 [34]
China Kidney dA-AAI Detected, but not quantified TLC 32P-postlabelling 2005 [81]
USA Kidney (cortex, medulla, and pelvis)Kidney (cortex)
dA-AA
dA-AAI
11.0–34 (n = 1)
Detected, but not quantified (n = 1)
PAGE 2 32P-postlabelling
Mass spectrometry 2007 [64]
Croatia Kidney dA-AA 8–59 (n = 4) PAGE 32P-postlabelling 2007 [64]
Taiwan Kidney dA-AA 1.4–234 (89/148 (60%)) PAGE 32P-postlabelling 2012 [72]
Bosnia, Croatia & Serbia Kidney dA-AA 0.2–19.2 (47/67 (70%)) PAGE 32P-postlabelling 2012 [65]
Romania Kidney dA-AAI 0.3–6.5 (n = 7) TLC 32P-postlabelling 2012 [30]
Belgium KidneyKidney
dA-AAI
dA-AAI
2–22 (n = 11) Detected, but not
quantified (n = 1) TLC
32P-postlabelling Mass spectrometry 2014 [53]
Croatia & Serbia Kidney dA-AAI 0.2–7.0 (n = 15) Mass spectrometry 2014 [82]
Belgium Kidney dA-AAI 5 (n = 1) TLC 32P-postlabelling 2015 [83]
Romania Kidney dA-AAI 0.7–26.8 (n = 14) Mass spectrometry 2016 [71]
Taiwan Kidney dA-AAI 0.3–258 (39/51 (76%)) Mass spectrometry 2016 [31]
1 Thin-layer chromatography, 2 Polyacrylamide gel electrophoresis.
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2.1.2. Mechanisms of Enzymatic Activation of AA to Metabolites Forming AA-Derived DNA Adducts
and Its Detoxification Resulting in Attenuation of AA-Mediated Diseases
Even though exposure to AA causes the development of UUC associated with AAN/BEN,
there are several questions that remained to be answered. Why do only 10–20% of patients in
the slimming clinic in Brussels developed AAN [35]? Similarly, only 5–10% of the residents in
endemic areas develop BEN [84,85]. In the case of BEN this cannot be attributed easily to preferential
exposure of such a small group of the population to AA, but it could result also from other factors.
Besides the route of AA exposure and its dose, metabolism determines the biological effective
concentration of AA in exposed individuals, which can dictate the development of AAN/BEN and
disease progression (i.e., urothelial malignancy). Several endogenous factors might also contribute to
disease development, e.g., the efficiencies of bioactivation and/or detoxification of AA, the expression
levels of biotransformation enzymes participating in AA metabolism and their activities as well as
their genetic and phenotypic polymorphisms.
There are two pathways of AA metabolism that are important for the development of
UUC-associated with AAN/BEN: (i) activation of AA to genotoxic intermediates generating DNA
adducts; and (ii) detoxification of AA resulting in a decrease in the actual AA concentrations that can
lead to the attenuation of nephropathy. The major metabolites of AAI and AAII found in urine and
faeces of several animal models and of humans are the aristolactams I and II (for structures of the
aristolactams, see Figure 2) [86–88]. Other minor metabolites formed through O-demethylation (i.e.,
the formation of 8-hydroxyaristolochic acid I (aristolochic acid Ia, AAIa)) and denitration have also
been reported [86–88]. The only metabolites identified in humans so far are the aristolactams I and II
found in urine [86].
AAI might directly cause interstitial nephropathy while enzymatic activation of AAI to
intermediates capable of binding to DNA is a necessary reaction leading to formation of AA-DNA
adducts that initiate malignant transformation. Both oxidative and reductive metabolites of AAI are
formed in vivo after AAI exposure and are excreted in urine and faeces (reviewed in [16,18,19]).
Formation of N-hydroxyaristolactam I is mediated by reduction of AAI and this metabolite is
either further reduced to aristolactam I or rearranged to 7-hydroxyaristolactam I (Figure 3) [87,88].
Aristolactam Ia is one additional AAI metabolite, which is predominantly formed in animal
models [87,88] and might be generated either from demethylation of aristolactam I or by reduction of
AAIa [89]. Oxidation of AAI leads to AAIa, which is the product of oxidative O-demethylation of AAI
and considered a detoxification metabolite [21,22,90] (Figure 3). Conversion of N-hydroxyaristolactam
I to the 7-hydroxyaristolactam I or further reduction to aristolactam I is considered as detoxification
pathway, because both metabolites are excreted [87,88]. Moreover, no DNA adducts are generated from
AAIa and 7-hydroxyaristolactam I in humans or in animal models (reviewed in [21,22]); essentially
no histological changes were determined in kidney of mice treated with AAIa [90]. In the case of
aristolactam I, treatment of rats led to ~50-fold lower levels of AAI-DNA adducts (i.e., dA-AAI and
dG-AAI) in the kidney than after AAI treatment [91].
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Figure 4. AAIa formation by human recombinant CYP enzymes in the presence of cytochrome b5 
(Cyb5) (A); Data shown are mean ± SD (n = 3). ND, not detected. Data previously published in 
[92,95,96] (A); Contributions of CYP enzymes to AAIa formation in human livers (B). 
The mechanism for differing efficacies of these CYPs found experimentally was explained by 
molecular modeling [96]. The major reasons for the differences observed are based mainly on the 
Figure 3. Activation and detoxification pathways of AAI. dA-AAI, 7-(deoxyadenosin-N6-yl)aristolactam
I; dG-AAI, 7-(deoxyguanos n-N2-yl)aristolactam I; CYP, cyt chrome P450; NQO1, NAD(P)H:quinone
oxidoreductase; POR, NADPH:CYP oxidoreductase.
Human cytochrome P450 (CYP) enzymes CYP1A1 and 1A2 are the predominant enzymes
oxidising AAI to AAIa under aerobic (i.e., oxidative) conditions [92–97]. Of other CYPs, CYP2C
(i.e., CYP2C8/9/19), CYP3A (i.e., CYP3A4/5), 2D6, 2E1 and 1B1 also form AAIa, but their efficiency
in catalysing this reaction is more than one order of magnitude lower compared to CYP1A
enzymes [92,95,96] (Figure 4A). In the liver human CYP1A2 followed by CYP2C9, CYP3A4 and
CYP1A1 are the major enzymes contributing to AAI oxidation (Figure 4B) [96].
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(A); Data shown are mean ± SD (n = 3). ND, not detected. Data previously published in [92,95,96] (A);
Contributions of CYP enzymes to AAIa formation in human livers (B).
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The mechanism for differing efficacies of these CYPs found experimentally was explained by
molecular modeling [96]. The major reasons for the differences observed are based mainly on the
finding that CYP2C9 and 3A4 enzymes bind the AAI molecule with a significantly lower affinity and
with less suitable orientation than the enzymes of the CYP1A subfamily [96].
The significance of CYP1A1 and 1A2 enzymes to oxidise AAI to AAIa in vivo was demonstrated
using Cyp1a-knockout and CYP1A-humanised mouse lines [92,94,97]. Additional studies were
performed in mice and rats where Cyp1a/CYP1A enzymes were enhanced by inducers [98,99]. It was
shown that murine Cyp1a1 and 1a2 oxidise AAI to AAIa and protect these animals from AAI-induced
acute renal injury [94,100]. Nephrotoxic effects were higher in AAI-treated mice lacking Cyp1a
compared to wild-type [94]. Moreover, induction of CYP1A1 and 1A2 in rats resulted in an increase in
AAI detoxification to AAIa, thereby reducing the actual concentration of AAI available for reductive
activation [98]. More importantly, AAI oxidation to AAIa by human CYP1A1 and 1A2 was also shown
in vivo using CYP1A-humanised mouse lines [92].
However, a recent study demonstrated that AAII is oxidised to a much lower extent (if any) than
AAI; essentially no AAIa or other oxidation products of AAII were found to be formed by microsomal
CYP enzymes in vitro [101]. Likewise, in rats exposed to AAII in vivo, no formation of AAIa from
AAII was observed [Stiborova et al., unpublished results]. This phenomenon suggests that AAII
is metabolised in organisms solely by reductive activation leading to the formation of AAII-DNA
adducts [18,20,21]. Interestingly, treatment of rats either with an artificial mixture of AAII and AAI or
the natural plant extract containing both AAI and AAII elevated the formation of not only AAII-, but
also AAI-derived DNA adducts compared to rats treated with the compounds alone [102]. However,
the mechanism of this increase is not yet known and remains to be investigated.
Initial reduction of AAI or AAII to the corresponding N-hydroxyaristolactams is the activation
pathway responsible for their genotoxic effects. As mentioned above, during this reaction AAI
or AAII are enzymatically reduced to cyclic acylnitrenium ions that are capable of binding to the
exocyclic amino groups of adenine and guanine in DNA (i.e., dA-AAI, dG-AAI, dA-AAII or dG-AAII)
(Figure 2) [42–46,62]. Comparing AAI to AAII, significantly higher levels of AAI-derived DNA adducts
than adducts derived from AAII were found in rats and mice in vivo [43,46,103–105] and in various
enzymatic systems in vitro [45,106–111]. However, in C3H/He mice exposed to equivalent doses of
AAI and AAII, lower levels of AAII-derived DNA adducts were found only in non-target organs
such as liver, stomach, intestine, and lung, in contrast to the primary target tissues such as renal
cortex, medulla and bladder (urothelial cells) where the same extent of DNA adducts was found [104].
The apparent discrepancies among the studies [103–105] might be attributed to several reasons such
as the use of various animal models, utilisation of different treatment protocols and/or employing
different methods for the detection of AA-DNA adducts. Nevertheless, differences in the levels of
AAI- and AAII-derived DNA adducts might also result from a different enzymatic conversion of these
carcinogens (i.e., activation and detoxification). Indeed, several studies showing that AAII is a poorer
substrate of the biotransformation enzymes in vitro than AAI support this conclusion [101,106–110].
Several human enzymes capable of activating AAI or AAII by nitroreduction have been identified.
Of them, cytosolic NAD(P)H:quinone oxidoreductase (NQO1) was found to be the major cytosolic
reductase activating AA both in vitro and in vivo [18–20,109–116], while cytosolic xanthine oxidase
plays a minor role [20,109,112,114]. The studies on the mechanism of AAI and AAII nitroreduction by
NQO1 indicated that direct transfers of electrons from NADPH is mediated through the isoalloxazine
ring of its reduced flavine prosthetic group (FAD) [47,110,115]. Moreover, hydroxylic groups of amino
acids Tyr128 and Tyr126 present in the NQO1 active site also contribute to AAI reduction; they stabilise
the AAI or AAII binding orientation in the NQO1 active site through hydrogen bonding of oxygens of
the nitro group [47,110,115].
Studies of several laboratories examining the role of phase II conjugation enzymes in the
formation of AAI- and AAII-DNA adducts showed controversial results [47,105,110,112,117–119].
No contribution of sulfotransferases (SULT), such as SULT1A, SULT1A3, SULT2E1, SULT2A1, and
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N,O-acetyltransferases (NATs) in the bioactivation of AAI and AAII was found in enzymatic cell-free
systems in vitro [47,110,112]. This also corresponded to results using human hepatic cytosolic
fractions where only NQO1 activity correlated with higher AAI-DNA adduct formation [112].
A recent study utilising transgenic mice carrying a functional human SULT1A1-SULT1A2 gene
cluster or mice with Sult1a1 knockout showed that conjugation with the active sulfate (i.e.,
3′-phosphoadenosine-5′-phosphosulfate [PAPS]) catalysed by human SULT1A1 and murine Sult1a1
do not contribute to bioactivation of AAI and AAII in vivo [105]. In contrast, Meinl et al. [119] showed
that expression of human SULT1A1 in bacterial and mammalian cells increased the mutagenicity AA.
Sidorenko et al. [117] found that O-sulfonated and O-acetylated N-hydroxyaristolactam I and II form
DNA adducts in vitro and that binding of N-hydroxyaristolactam I and II to DNA was stimulated
by mouse cytosol in the presence of the cofactor PAPS [112]. Moreover, human SULT1B1, SULT1A1
and SULT1A2 were capable of stimulating DNA adduct formation by N-hydroxyaristolactam I and
II [117]. Likewise, Hashimoto et al. [118] showed that activation of AAI and N-hydroxyaristolactam I
is potentiated by SULT1A1 in human HK-2 kidney and skin fibroblast GM00637 cells. Consequently,
further studies are necessary to resolve the reasons responsible for these discrepancies, for example
whether different experimental approaches used in these studies might be the reason.
Human microsomal enzymes such as CYPs are also capable of reducing AAI and AAII, while
NADPH:CYP oxidoreductase (POR), another microsomal enzyme, plays only a minor role in
nitroreduction of these compounds [18,20,21,95,96,106,107,114,120–122]. Of human enzymes, CYP1A1
and 1A2 are the only enzymes that are able to efficiently activate AAI (Figure 5) and AAII [106] by
nitroreduction under anaerobic conditions, while other CYPs are almost ineffective in catalysing this
reaction. In contrast to CYP1A1 and 1A2, the closely related CYP1B1, which is lacking the hydroxyl
group containing amino acid residues in its active site, is ineffective in catalysing AAI nitroreductase
activity (see Figure 5) [120,122,123].
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The mechanisms of CYP-mediated reduction, which is a rather rare case for CYP-catalysing
reactions [124,125], have been explained for AAI utilising molecular modeling [123] and site-directed
mutagenesis studies [122]. The hydroxyl groups of amino acids Ser122/Thr124 in CYP1A1 and 1A2,
which are located closed to the nitro group of AAI in the CYP1A1/1A2-AAI binary complexes
are necessary for the reaction as they provide the proton required for the stepwise reduction
reaction. In contrast, the closely related CYP1B1, which is lacking the hydroxyl group containing
residues in its active site (Ala is present instead of Ser or Thr), is ineffective in catalysing AAI
nitroreduction [115,122,123]. Participation of CYP1A1 and 1A2 in the reductive activation of AAI was
also demonstrated in rodents in vivo. Experimental in vivo models employed in these studies included
Hepatic Reductase Null (HRN) [90], Cyp1a1(−/−), Cyp1a2(−/−) and Cyp1a1/1a2(−/−) [94,97] mouse
lines. CYP1A-humanised mouse lines that carried functional human CYP1A1 and CYP1A2 genes and
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lack the mouse orthologous genes confirmed the importance of human CYP1A1 and CYP1A2 in AAI
bioactivation in vivo [92].
The function of CYP1A1 and 1A2 both in the reductive and oxidative metabolism of AAI can
be explained by different binding orientations of this compound in the CYP1A1 and 1A2 active sites
dependent on concentrations of oxygen. AAI acts as a ligand substrate for these human enzymes,
where it is bound to the heme iron instead of molecular oxygen, and is therefore reduced instead of
being oxidised during the CYP-mediated reaction cycle [20,122,123]. Under oxidative conditions, AAI
is a classical substrate of CYP1A1 and 1A2, being bound to Compound I (the highly reactive CYP
intermediate that is responsible for the CYP-mediated oxidations) of these CYP enzymes. During this
process one atom of molecular oxygen is used to O-demethylate the methoxy group of AAI to generate
AAIa [20,115]. The dual role of CYP1A1 and 1A2 (oxidation versus reduction of AAI) is an important
phenomenon, because a balance between reductive activation and oxidative detoxification reactions of
AAI is considered to be a critical determinant in the development of AAN/BEN.
The identification of the enzymes metabolising AA (mainly NQO1, CYP1A1/2, CYP2C9,
and CYP3A4/5,) is the first and essential step in the evaluation of their contribution to different
susceptibility of individuals to this carcinogen and nephrotoxin. Expression levels of these enzymes
and their activities might depend on various factors such as their basal expression, regulation, induction
and/or inhibition [126] as well as their polymorphisms [127]. All of the above-mentioned enzymes are
inducible and their expression can be modulated both by exogenous (environmental) chemicals or
drugs and by endogenous compounds such as several hormones (reviewed in [126–129]). Moreover, it
should be emphasised that exposure to AA itself can induce and/or inhibit some of these enzyme (e.g.,
NQO1 and CYP1A1/2) [97,98,130].
In addition to these factors, genetic polymorphisms in NQO1, CYP1A1/2, CYP2C9 and CYP3A4/5
might also impact on an individual’s susceptibility to AA. The role of some genetic polymorphisms of
biotransformation enzymes (NQO1, CYP1A1, CYP2D6, CYP3A4/5, NAT1/2, glutathione-S-transferase
(GST) GSTT1, GSTM1, GSTP1 and GSTA1) has already been examined in BEN/AAN patients
(for a review, see [21,127,131–138]). However, studies investigating the associations of genetic
polymorphisms of the enzymes metabolising AA and the risk of developing AAN/BEN and UUC
have reported controversial results. Therefore, the real impact of these enzymes on disease still
remains to be understood. One of the reasons for these controversial findings might result from the
fact that investigations only focus on genetic polymorphisms without taking the actual expression
levels of the enzymatically active proteins into account. Therefore, analyses of the expression levels of
enzymes metabolising AA and their phenotyping in AAN/BEN patients are the challenge to receive
more valuable data on determination how individual enzymes metabolising AA really contribute to
AA-mediated nephropathy and cancer risk among these patients.
3. Conclusions
The data described in this review underline the fact that chronic intoxication of humans with AA,
a plant product of Aristolochia species, is the main causal agent for the development of AAN/BEN
and associated UUC. This conclusion is based on similarities of the pathology of AAN and BEN,
the detection of specific AA-derived DNA adducts in renal tissue of the patients suffering from
these diseases and the dominance of the A:T to T:A transversion mutations in the cancer genomes
of these patients. The formation of AA-DNA adducts should be utilised not only as a biomarker
for the assessment of AA exposure and risk of UUC, but also be used in mechanistic investigations
studying host factors (e.g., enzymes catalysing AA metabolism or DNA repair pathways that may
remove AA-DNA adducts) that are critical determinants in mediating the risk for AA-induced UUC.
Moreover, because the distribution of Aristolochia species is worldwide and the use of medicinal herbal
remedies containing AA is still widespread, AA might be the cause of yet un-recognised nephropathies
and UUC.
Int. J. Mol. Sci. 2017, 18, 2144 12 of 19
Acknowledgments: This work was supported by the Grant Agency of the Czech Republic (grant GACR
17–12816S). Work at King’s College London was also supported by Cancer Research UK (grant number
C313/A14329), the Welcome Trust (Grants 101126/Z/13/Z and 101126/B/13/Z), Natural Environmental Research
Council (Grant NE/L006782/1) and in part in part by the National Institute for Health Research Health Protection
Research Unit (NIHR HPRU) in Health Impact of Environmental Hazards at King’s College London in partnership
with Public Health England (PHE). The views expressed are those of the authors and not necessarily those of the
National Health Service, the NIHR, the Department of Health or PHE.
Author Contributions: Conception, design interpretation of the data: Marie Stiborová, Volker M. Arlt and
Heinz H. Schmeiser; Drafting of the article: Marie Stiborová Critical revision of the article for important intellectual
content: Marie Stiborová, Volker M. Arlt and Heinz H. Schmeiser.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Poirier, M. Chemical-induced DNA damage and human cancer risk. Nat. Rev. Cancer 2004, 4, 630–637.
[CrossRef] [PubMed]
2. Poirier, M.C. Chemical-induced DNA damage and human cancer risk. Discov. Med. 2012, 14, 283–288.
[CrossRef] [PubMed]
3. Poirier, M.C. Linking DNA adduct formation and human cancer risk in chemical carcinogenesis. Environ. Mol.
Mutagen. 2016, 57, 499–507. [CrossRef] [PubMed]
4. Loeb, L.A.; Harris, C.C. Advances in chemical carcinogenesis: A historical review and prospective. Cancer Res.
2008, 68, 6863–6872. [CrossRef] [PubMed]
5. Guengerich, F.P. Metabolism of chemical carcinogens. Carcinogenesis 2000, 21, 345–351. [CrossRef] [PubMed]
6. Phillips, D.H. DNA adducts as markers of exposure and risk. Mutat. Res. 2005, 577, 284–292. [CrossRef]
[PubMed]
7. Phillips, D.H. The Formation of DNA Adducts. In Cancer Handbook; Wiley: Hoboken, NJ, USA, 2007.
8. Phillips, D.H.; Arlt, V.M. Genotoxicity: Damage to DNA and its consequences. EXS 2009, 99, 87–110.
[PubMed]
9. Baird, W.M.; Hooven, L.A.; Mahadevan, B. Carcinogenic polycyclic aromatic hydrocarbon-DNA adducts
and mechanism of action. Environ. Mol. Mutagen. 2005, 45, 106–114. [CrossRef] [PubMed]
10. Turesky, R.J.; le Marchand, L. Metabolism and biomarkers of heterocyclic aromatic amines in molecular
epidemiology studies: Lessons learned from aromatic amines. Chem. Res. Toxicol. 2011, 24, 1169–1214.
[CrossRef] [PubMed]
11. Phillips, D.H.; Arlt, V.M. The 32P-postlabeling assay for DNA adducts. Nat. Protoc. 2007, 2, 2772–2781.
[CrossRef] [PubMed]
12. Phillips, D.H.; Venitt, S. DNA and protein adducts in human tissues resulting from exposure to tobacco
smoke. Int. J. Cancer 2012, 131, 2733–2753. [CrossRef] [PubMed]
13. Rappaport, S.M.; Li, H.; Grigoryan, H.; Funk, W.E.; Williams, E.R. Adductomics: Characterizing exposures
to reactive electrophiles. Toxicol. Lett. 2012, 213, 83–90. [CrossRef] [PubMed]
14. Harris, C.C. 1995 Deichmann Lecture—p53 tumor suppressor gene: At the crossroads of molecular
carcinogenesis, molecular epidemiology and cancer risk assessment. Toxicol. Lett. 1995, 82–83, 1–7. [CrossRef]
15. Wogan, G.N.; Kensler, T.W.; Groopman, J.D. Present and future directions of translational research on
aflatoxin and hepatocellular carcinoma. A review. Food Addit. Contam. Part. A Chem. Anal. Control Expo.
Risk Assess. 2012, 29, 249–257. [CrossRef] [PubMed]
16. Arlt, V.M.; Stiborova, M.; Schmeiser, H.H. Aristolochic acid as a probable human cancer hazard in herbal
remedies: A review. Mutagenesis 2002, 17, 265–277. [CrossRef] [PubMed]
17. Stiborova, M.; Frei, E.; Arlt, V.M.; Schmeiser, H.H. The role of biotransformation enzymes in the development
of renal injury and urothelial cancer caused by aristolochic acid: urgent questions and difficult answers.
Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. 2009, 153, 5–11. [CrossRef] [PubMed]
18. Stiborová, M.; Frei, E.; Arlt, V.M.; Schmeiser, H.H. Metabolic activation of carcinogenic aristolochic acid,
a risk factor for Balkan endemic nephropathy. Mutat. Res. 2008, 658, 55–67. [CrossRef] [PubMed]
19. Stiborová, M.; Frei, E.; Schmeiser, H.H. Biotransformation enzymes in development of renal injury and
urothelial cancer caused by aristolochic acid. Kidney Int. 2008, 73, 1209–1211. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 2144 13 of 19
20. Stiborová, M.; Martínek, V.; Frei, E.; Arlt, V.M.; Schmeiser, H.H. Enzymes metabolizing aristolochic acid and
their contribution to the development of Aristolochic acid nephropathy and urothelial cancer. Curr. Drug
Metab. 2013, 14, 695–705. [CrossRef] [PubMed]
21. Stiborová, M.; Arlt, V.M.; Schmeiser, H.H. Balkan endemic nephropathy: An update on its aetiology.
Arch. Toxicol. 2016, 90, 2595–2615. [CrossRef] [PubMed]
22. Schmeiser, H.H.; Stiborova, M.; Arlt, V.M. Chemical and molecular basis of the carcinogenicity of Aristolochia
plants. Curr. Opin. Drug Discov. Dev. 2009, 12, 141–148.
23. Gökmen, M.R.; Cosyns, J.P.; Arlt, V.M.; Stiborová, M.; Phillips, D.H.; Schmeiser, H.H.; Simmonds, M.S.J.;
Look, H.T.; Vanherweghem, J.L.; Nortier, J.L.; et al. The epidemiology, diagnosis and management of
Aristolochic Acid Nephropathy: A narrative review. Ann. Intern. Med. 2013, 158, 469–477. [CrossRef]
[PubMed]
24. Grollman, A.P. Aristolochic acid nephropathy: Harbinger of a global iatrogenic disease. Environ. Mol. Mutagen.
2013, 54, 1–7. [CrossRef] [PubMed]
25. Schmeiser, H.H.; Pool, B.L.; Wiessler, M. Mutagenicity of the two main components of commercially available
carcinogenic aristolochic acid in Salmonella typhimurium. Cancer Lett. 1984, 23, 97–101. [CrossRef]
26. Kohara, A.; Suzuki, T.; Honma, M.; Ohwada, T.; Hayashi, M. Mutagenicity of aristolochic acid in the
lambda/lacZ transgenic mouse (MutaMouse). Mutat. Res. 2002, 515, 63–72. [CrossRef]
27. Nortier, J.L.; Martinez, M.C.; Schmeiser, H.H.; Arlt, V.M.; Bieler, C.A.; Petein, M.; Depierreux, M.F.;
de Pauw, L.; Abramowicz, D.; Vereerstraeten, P.; et al. Urothelial carcinoma associated with the use of
a Chinese herb (Aristolochia fangchi). N. Engl. J. Med. 2000, 342, 1686–1692. [CrossRef] [PubMed]
28. Mei, N.; Arlt, V.M.; Phillips, D.H.; Heflich, R.H.; Chen, T. DNA adduct formation and mutation induction by
aristolochic acid in rat kidney and liver. Mutat. Res. 2006, 602, 83–91. [CrossRef] [PubMed]
29. International Agency for Research on Cancer (IARC). A review of human CARCINOGENS: Pharmaceuticals.
In Environmental Health Criteria Monographs; World Health Organization: Geneva, Switzerland, 2012.
30. Schmeiser, H.H.; Kucab, J.E.; Arlt, V.M.; Phillips, D.H.; Hollstein, M.; Gluhovschi, G.; Gluhovschi, C.;
Modilca, M.; Daminescu, L.; Petrica, L.; et al. Evidence of exposure to aristolochic acid in patients with
urothelial cancer from a Balkan endemic nephropathy region of Romania. Environ. Mol. Mutagen. 2012, 53,
636–641. [CrossRef] [PubMed]
31. Hoang, M.L.; Chen, C.H.; Chen, P.C.; Roberts, N.J.; Dickman, K.G.; Yun, B.H.; Turesky, R.J.; Pu, Y.S.;
Vogelstein, B.; Papadopoulos, N.; et al. Aristolochic acid in the etiology of renal cell carcinoma.
Cancer Epidemiol. Biomark. Prev. 2016, 25, 1600–1608. [CrossRef] [PubMed]
32. Rosenquist, T.A.; Grollman, A.P. Mutational signature of aristolochic acid: Clue to the recognition of a global
disease. DNA Repair 2016, 44, 205–2011. [CrossRef] [PubMed]
33. Vanherweghem, J.L.; Tielemans, C.; Abramowicz, D.; Depierreux, M.; Vanhaelen-Fastre, R.; Vanhaelen, M.;
Dratwa, M.; Richard, C.; Vandervelde, D.; Verbeelen, D.; et al. Rapidly progressive interstitial renal fibrosis
in young women: Association with slimming regimen including Chinese herbs. Lancet 1993, 341, 387–391.
[CrossRef]
34. Arlt, V.M.; Alunni-Perret, V.; Quatrehomme, G.; Ohayon, P.; Albano, L.; Gaïd, H.; Michiels, J.F.; Meyrier, A.;
Cassuto, E.; Wiessler, M.; et al. Aristolochic acid (AA)-DNA adduct as marker of AA exposure and risk
factor for AA nephropathy-associated cancer. Int. J. Cancer 2004, 111, 977–980. [CrossRef] [PubMed]
35. Debelle, F.D.; Vanherweghem, J.L.; Nortier, J.L. Aristolochic acid nephropathy: A worldwide problem.
Kidney Int. 2008, 74, 158–169. [CrossRef] [PubMed]
36. Cosyns, J.P.; Goebbels, R.M.; Liberton, V.; Schmeiser, H.H.; Bieler, C.A.; Bernard, A.M. Chinese herbs
nephropathy-associated slimming regimen induces tumours in the forestomach but no interstitial
nephropathy in rats. Arch. Toxicol. 1998, 72, 738–743. [CrossRef] [PubMed]
37. Cosyns, J.P.; Jadoul, M.; Squifflet, J.P.; Wese, F.X.; van Ypersele de Strihou, C. Urothelial lesions in Chinese
herb nephropathy. Am. J. Kidney Dis. 1999, 33, 1011–1017. [CrossRef]
38. Jin, K.; Su, K.K.; Li, T.; Zhu, X.Q.; Wang, Q.; Ge, R.S.; Pan, Z.F.; Wu, B.W.; Ge, L.J.; Zhang, Y.H.; et al. Hepatic
Premalignant Alterations Triggered by Human Nephrotoxin Aristolochic Acid I in Canines. Cancer Prev.
Res. (Phila) 2016, 9, 324–334. [CrossRef] [PubMed]
39. Li, T.; Jin, K.; Zhu, D.Y.; Li, L.; Mao, Z.R.; Wu, B.W.; Wang, Y.F.; Pan, Z.F.; Li, L.J.; Xiang, C.S.; et al.
Premalignant alteration assessment in liver-like tissue derived from embryonic stem cells by aristolochic
acid I exposure. Oncotarget 2016, 7, 78872–78882. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 2144 14 of 19
40. Jadot, I.; Declèves, A.E.; Nortier, J.; Caron, N. An integrated view of Aristolochic acid nephropathy: Update
of the literature. Int. J. Mol. Sci. 2017, 18, 297. [CrossRef] [PubMed]
41. Chan, W.; Pavlovic´, N.M.; Li, W.; Chan, C.K.; Liu, J.; Deng, K.; Wang, Y.; Milosavljevic´, B.; Kostic´, E.N.
Quantitation of Aristolochic Acids in Corn, Wheat Grain, and Soil Samples Collected in Serbia: Identifying a
Novel Exposure Pathway in the Etiology of Balkan Endemic Nephropathy. J. Agric. Food Chem. 2016, 64,
5928–5934. [CrossRef] [PubMed]
42. Pfau, W.; Schmeiser, H.H.; Wiessler, M. Aristolochic acid binds covalently to the exocyclic amino group of
purine nucleotides in DNA. Carcinogenesis 1990, 11, 313–319. [CrossRef] [PubMed]
43. Pfau, W.; Schmeiser, H.H.; Wiessler, M. 32P-postlabelling analysis of the DNA adducts formed by aristolochic
acid I and II. Carcinogenesis 1990, 11, 1627–1633. [CrossRef] [PubMed]
44. Schmeiser, H.H.; Bieler, C.A.; Wiessler, M.; van Ypersele de Strihou, C.; Cosyns, J.P. Detection of DNA
adducts formed by aristolochic acid in renal tissue from patients with Chinese herbs nephropathy. Cancer Res.
1996, 56, 2025–2028. [PubMed]
45. Schmeiser, H.H.; Frei, E.; Wiessler, M.; Stiborová, M. Comparison of DNA adduct formation by aristolochic
acids in various in vitro activation systems by 32P-post-labelling: Evidence for reductive activation by
peroxidases. Carcinogenesis 1997, 18, 1055–1062. [CrossRef] [PubMed]
46. Stiborová, M.; Fernando, R.C.; Schmeiser, H.H.; Frei, E.; Pfau, W.; Wiessler, M. Characterization of DNA
adducts formed by aristolochic acids in the target organ (forestomach) of rats by 32P-postlabelling analysis
using different chromatographic procedures. Carcinogenesis 1994, 15, 1187–1192. [CrossRef] [PubMed]
47. Stiborová, M.; Mareš, J.; Frei, E.; Arlt, V.M.; Martínek, V.; Schmeiser, H.H. The human carcinogen aristolochic
acid I is activated to form DNA adducts by human NAD(P)H:quinone oxidoreductase without the
contribution of acetyltransferases or sulfotransferases. Environ. Mol. Mutagen. 2011, 52, 448–459. [CrossRef]
[PubMed]
48. Lord, G.M.; Cook, T.; Arlt, V.M.; Schmeiser, H.H.; Williams, G.; Pusey, C.D. Urothelial malignant disease and
Chinese herbal nephropathy. Lancet 2001, 358, 1515–1516. [CrossRef]
49. Lord, G.M.; Hollstein, M.; Arlt, V.M.; Roufosse, C.; Pusey, C.D.; Cook, T.; Schmeiser, H.H. DNA adducts
and p53 mutations in a patient with aristolochic acid-associated nephropathy. Am. J. Kidney Dis. 2004, 43,
e11–e17. [CrossRef] [PubMed]
50. Arlt, V.M.; Stiborova, M.; vom Brocke, J.; Simoes, M.L.; Lord, G.M.; Nortier, J.L.; Hollstein, M.; Phillips, D.H.;
Schmeiser, H.H. Aristolochic acid mutagenesis: Molecular clues to the aetiology of Balkan endemic
nephropathy-associated urothelial cancer. Carcinogenesis 2007, 28, 2253–2261. [CrossRef] [PubMed]
51. Aydin, S.; Dekairelle, A.F.; Ambroise, J.; Durant, J.F.; Heusterspreute, M.; Guiot, Y.; Cosyns, J.P.; Gala, J.L.
Unambiguous detection of multiple TP53 gene mutations in AAN-associated urothelial cancer in Belgium
using laser capture microdissection. PLoS ONE 2014, 9, e106301. [CrossRef] [PubMed]
52. Aydin, S.; Ambroise, J.; Cosyns, J.P.; Gala, J.L. TP53 mutations in p53-negative dysplastic urothelial cells
from Belgian AAN patients: New evidence for aristolochic acid-induced molecular pathogenesis and
carcinogenesis. Mutat. Res. 2017, 818, 17–26. [CrossRef] [PubMed]
53. Schmeiser, H.H.; Nortier, J.L.; Singh, R.; Gamboa da Costa, G.; Sennesael, J.; Cassuto-Viguier, E.;
Ambrosetti, D.; Rorive, S.; Pozdzik, A.; Phillips, D.H.; et al. Exceptionally long-term persistence of DNA
adducts formed by carcinogenic aristolochic acid I in renal tissue from patients with aristolochic acid
nephropathy. Int. J. Cancer 2014, 135, 562–567. [CrossRef]
54. Schmeiser, H.H.; Janssen, J.W.; Lyons, J.; Scherf, H.R.; Pfau, W.; Buchmann, A.; Bartram, C.R.; Wiessler, M.
Aristolochic acid activates ras genes in rat tumors at deoxyadenosine residue. Cancer Res. 1990, 50, 5464–5469.
[PubMed]
55. Schmeiser, H.H.; Scherf, H.R.; Wiessler, M. Activating mutations at codon 61 of the c-Ha-ras gene in
thin-tissue sections of tumors induced by aristolochic acid in rats and mice. Cancer Lett. 1991, 59, 139–143.
[CrossRef]
56. Wang, Y.; Meng, F.; Arlt, V.M.; Mei, N.; Chen, T.; Parsons, B.L. Aristolochic acid-induced carcinogenesis
examined by ACB-PCR quantification of H-Ras and K-Ras mutant fraction. Mutagenesis 2011, 26, 619–628.
[CrossRef] [PubMed]
57. Wang, Y.; Arlt, V.M.; Roufosse, C.A.; McKim, K.L.; Myers, M.B.; Phillips, D.H.; Parsons, B.L. ACB-PCR
measurement of H-ras codon 61 CAA→CTA mutation provides an early indication of aristolochic acid I
carcinogenic effect in tumor target tissues. Environ. Mol. Mutagen. 2012, 53, 495–504. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 2144 15 of 19
58. Broschard, T.H.; Wiessler, M.; von der Lieth, C.W.; Schmeiser, H.H. Translesional synthesis on DNA templates
containing site-specifically placed deoxyadenosine and deoxyguanosine adducts formed by the plant
carcinogen aristolochic acid. Carcinogenesis 1994, 15, 2331–2340. [CrossRef] [PubMed]
59. Moriya, M.; Slade, N.; Brdar, B.; Medverec, Z.; Tomic, K.; Jelakovic, B.; Wu, L.; Truong, S.; Fernandes, A.;
Grollman, A.P. TP53 Mutational signature for aristolochic acid: An environmental carcinogen. Int. J. Cancer
2011, 129, 1532–1536. [CrossRef] [PubMed]
60. Olivier, M.; Hollstein, M.; Schmeiser, H.H.; Straif, K.; Wild, C.P. Upper urinary tract urothelial cancer: Where
it is A:T. Nat. Rev. Cancer 2012, 12, 503–504. [CrossRef] [PubMed]
61. Arlt, V.M.; Pfohl-Leszkowicz, A.; Cosyns, J.; Schmeiser, H.H. Analyses of DNA adducts formed by ochratoxin
A and aristolochic acid in patients with Chinese herbs nephropathy. Mutat. Res. 2001, 494, 143–150.
[CrossRef]
62. Bieler, C.A.; Stiborová, M.; Wiessler, M.; Cosyns, J.-P.; van Ypersele de Strihou, C.; Schmeiser, H.H.
32P-postlabelling analysis of DNA adducts formed by aristolochic acid in tissues from patients with Chinese
herbs nephropathy. Carcinogenesis 1997, 18, 1063–1067. [CrossRef] [PubMed]
63. Arlt, V.M.; Ferluga, D.; Stiborova, M.; Pfohl-Leszkowicz, A.; Vukelic, M.; Ceovic, S.; Schmeiser, H.H.;
Cosyns, J.P. Is aristolochic acid a risk factor for Balkan endemic nephropathy-associated urothelial cancer?
Int. J. Cancer 2002, 101, 500–502. [CrossRef] [PubMed]
64. Grollman, A.P.; Shibutani, S.; Moriya, M.; Miller, F.; Wu, L.; Moll, U.; Suzuki, N.; Fernandes, A.; Rosenquist, T.;
Medverec, Z.; et al. Aristolochic acid and the etiology of endemic Balkan nephropathy. Proc. Natl. Acad.
Sci. USA 2007, 104, 12129–12134. [CrossRef] [PubMed]
65. Jelakovic´, B.; Karanovic´, S.; Vukovic´-Lela, I.; Miller, F.; Edwards, K.L.; Nikolic´, J.; Tomic´, K.; Slade, N.;
Brdar, B.; Turesky, R.J.; et al. Aristolactam-DNA adducts are a biomarker of environmental exposure to
aristolochic acid. Kidney Int. 2012, 81, 559–567. [CrossRef] [PubMed]
66. Yun, B.H.; Rosenquist, T.A.; Sidorenko, V.; Iden, C.R.; Chen, C.H.; Pu, Y.S.; Bonala, R.; Johnson, F.;
Dickman, K.G.; Grollman, A.P.; et al. Biomonitoring of aristolactam-DNA adducts in human tissues
using ultra-performance liquid chromatography/ion-trap mass spectrometry. Chem. Res. Toxicol. 2012, 25,
1119–1131. [CrossRef] [PubMed]
67. Yun, B.H.; Rosenquist, T.A.; Nikolic´, J.; Dragicˇevic´, D.; Tomic´, K.; Jelakovic´, B.; Dickman, K.G.; Grollman, A.P.;
Turesky, R.J. Human formalin-fixed paraffin-embedded tissues: An untapped specimen for biomonitoring of
carcinogen DNA adducts by mass spectrometry. Anal. Chem. 2013, 85, 4251–4258. [CrossRef] [PubMed]
68. Yun, B.H.; Sidorenko, V.S.; Rosenquist, T.A.; Dickman, K.G.; Grollman, A.P.; Turesky, R.J. New approaches
for biomonitoring exposure to the human carcinogen aristolochic acid. Toxicol. Res. (Camb) 2015, 4, 763–776.
[CrossRef] [PubMed]
69. Schmeiser, H.H.; Stiborova, M.; Arlt, V.M. 32P-postlabeling analysis of DNA adducts. Methods Mol. Biol.
2013, 1044, 389–401. [CrossRef] [PubMed]
70. Scelo, G.; Riazalhosseini, Y.; Greger, L.; Letourneau, L.; Gonzàlez-Porta, M.; Wozniak, M.B.; Bourgey, M.;
Harnden, P.; Egevad, L.; Jackson, S.M.; et al. Variation in genomic landscape of clear cell renal cell carcinoma
across Europe. Nat. Commun. 2014, 5, 5135. [CrossRef] [PubMed]
71. Turesky, R.J.; Yun, B.H.; Brennan, P.; Mates, D.; Jinga, V.; Harnden, P.; Banks, R.E.; Blanche, H.; Bihoreau, M.T.;
Chopard, P.; et al. Aristolochic acid exposure in Romania and implications for renal cell carcinoma.
Br. J. Cancer 2016, 114, 76–80. [CrossRef] [PubMed]
72. Chen, C.H.; Dickman, K.G.; Moriya, M.; Zavadil, J.; Sidorenko, V.S.; Edwards, K.L.; Gnatenko, D.V.; Wu, L.;
Turesky, R.J.; Wu, X.R.; et al. Aristolochic acid-associated urothelial cancer in Taiwan. Proc. Natl. Acad.
Sci. USA 2012, 109, 8241–8246. [CrossRef] [PubMed]
73. Chen, C.H.; Dickman, K.G.; Huang, C.Y.; Shun, C.T.; Tai, H.C.; Huang, K.H.; Wang, S.M.; Lee, Y.J.;
Grollman, A.P.; Pu, Y.S. Recurrence pattern and TP53 mutation in upper urinary tract urothelial carcinoma.
Oncotarget 2016, 7, 45225–45236. [CrossRef] [PubMed]
74. Hoang, M.L.; Chen, C.H.; Sidorenko, V.S.; He, J.; Dickman, K.G.; Yun, B.H.; Moriya, M.; Niknafs, N.;
Douville, C.; Karchin, R.; et al. Mutational signature of aristolochic acid exposure as revealed by whole-exome
sequencing. Sci. Transl. Med. 2013, 5, 197ra102. [CrossRef] [PubMed]
75. Poon, S.L.; Pang, S.T.; McPherson, J.R.; Yu, W.; Huang, K.K.; Guan, P.; Weng, W.H.; Siew, E.Y.; Liu, Y.;
Heng, H.L.; et al. Genome-wide mutational signatures of aristolochic acid and its application as a screening
tool. Sci. Transl. Med. 2013, 5, 197ra101. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 2144 16 of 19
76. Sidorenko, V.S.; Yeo, J.E.; Bonala, R.R.; Johnson, F.; Schärer, O.D.; Grollman, A.P. Lack of recognition
by global-genome nucleotide excision repair accounts for the high mutagenicity and persistence of
aristolactam-DNA adducts. Nucleic Acids Res. 2012, 40, 2494–2505. [CrossRef] [PubMed]
77. Nik-Zainal, S.; Kucab, J.E.; Morganella, S.; Glodzik, D.; Alexandrov, L.B.; Arlt, V.M.; Weninger, A.;
Hollstein, M.; Stratton, M.R.; Phillips, D.H. The genome as a record of environmental exposure. Mutagenesis
2015, 30, 763–770. [CrossRef] [PubMed]
78. National Toxicology Program. Aristolochic Acids 12th Report on Carcinogens; National Toxicology Program;
Public Health Service, US Department of Health and Human Services: Research Triangle Park, NC, USA,
2009; pp. 45–49.
79. Gillerot, G.; Jadoul, M.; Arlt, V.M.; van Ypersele de Strihou, C.; Schmeiser, H.H.; But, P.P.; Bieler, C.A.;
Cosyns, J.P. Aristolochic acid nephropathy in a Chinese patient: Time to abandon the term “Chinese herbs
nephropathy”? Am. J. Kidney Dis. 2001, 38, E26. [CrossRef] [PubMed]
80. Nortier, J.L.; Schmeiser, H.H.; Muniz Martinez, M.C.; Arlt, V.M.; Vervaet, C.; Garbar, C.H.; Daelemans, P.;
Vanherweghem, J.L. Invasive urothelial carcinoma after exposure to Chinese herbal medicine containing
aristolochic acid may occur without severe renal failure. Nephrol. Dial. Transplant. 2003, 18, 426–428.
[CrossRef] [PubMed]
81. Lo, S.H.; Wong, K.S.; Arlt, V.M.; Phillips, D.H.; Lai, C.K.; Poon, W.T.; Chan, C.K.; Mo, K.L.; Chan, K.W.;
Chan, A. Detection of Herba Aristolochia Mollissemae in a patient with unexplained nephropathy. Am. J.
Kidney Dis. 2005, 45, 407–410. [CrossRef] [PubMed]
82. Yun, B.H.; Yao, L.; Jelakovic´, B.; Nikolic´, J.; Dickman, K.G.; Grollman, A.P.; Rosenquist, T.A.; Turesky, R.J.
Formalin-fixed paraffin-embedded tissue as a source for quantitation of carcinogen DNA adducts:
Aristolochic acid as a prototype carcinogen. Carcinogenesis 2014, 35, 2055–2061. [CrossRef] [PubMed]
83. Roumeguère, T.; Broeders, N.; Jayaswal, A.; Rorive, S.; Quackels, T.; Pozdzik, A.; Arlt, V.M.; Schmeiser, H.H.;
Nortier, J.L. Bacillus Calmette-Guerin therapy in non-muscle-invasive bladder carcinoma after renal
transplantation for end-stage aristolochic acid nephropathy. Transpl. Int. 2015, 28, 199–205. [CrossRef]
[PubMed]
84. Bamias, G.; Boletis, J. Balkan nephropathy: Evolution of our knowledge. Am. J. Kidney Dis. 2008, 52, 606–616.
[CrossRef] [PubMed]
85. Tatu, C.A.; Orem, W.H.; Finkelman, R.B.; Feder, G.L. The etiology of Balkan endemic nephropathy: Still
more questions than answers. Environ. Health Perspect. 1998, 106, 689–700. [PubMed]
86. Krumbiegel, G.; Hallensleben, J.; Mennicke, W.H.; Rittmann, N. Studies on the metabolism of aristolochic
acids I and II. Xenobiotica 1987, 17, 981–991. [CrossRef] [PubMed]
87. Chan, W.; Cu, L.; Xu, G.; Cai, Z. Study of the phase I and phase II metabolism of nephrotoxin aristolochic acid
by liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 2006, 20, 1755–1760.
[CrossRef] [PubMed]
88. Chan, W.; Luo, H.B.; Zheng, Y.; Cheng, Y.K.; Cai, Z. Investigation of the metabolism and reductive activation
of carcinogenic aristolochic acid in rats. Drug Metab. Dispos. 2007, 35, 866–874. [CrossRef] [PubMed]
89. Schmeiser, H.H.; Pool, B.L.; Wiessler, M. Identification and mutagenicity of metabolites of aristolochic acid
formed by rat liver. Carcinogenesis 1986, 7, 759–763. [CrossRef]
90. Shibutani, S.; Bonala, R.R.; Rosenquist, T.; Rieger, R.; Suzuki, N.; Johnson, F.; Miller, F.; Grollman, A.P.
Detoxification of aristolochic acid I by O-demethylation: Less nephrotoxicity and genotoxicity of aristolochic
acid Ia in rodents. Int. J. Cancer 2010, 127, 1021–1027. [CrossRef] [PubMed]
91. Dong, H.; Suzuki, N.; Torres, M.C.; Bonala, R.R.; Johnson, F.; Grollman, A.P.; Shibutani, S. Quantitative
determination of aristolochic acid-derived DNA adducts in rats using 32P-postlabeling/polyacrylamide gel
electrophoresis analysis. Drug Metab. Dispos. 2006, 34, 1122–1127. [CrossRef] [PubMed]
92. Stiborová, M.; Levová, K.; Bárta, F.; Shi, Z.; Frei, E.; Schmeiser, H.H.; Nebert, D.W.; Phillips, D.H.; Arlt, V.M.
Bioactivation versus detoxication of the urothelial carcinogen aristolochic acid I by human cytochrome P450
1A1 and 1A2. Toxicol. Sci. 2012, 125, 345–358. [CrossRef] [PubMed]
93. Sistkova, J.; Hudecek, J.; Hodek, P.; Frei, E.; Schmeiser, H.H.; Stiborova, M. Human cytochromes P450 1A1
and 1A2 participate in detoxication of carcinogenic aristolochic acid. Neuro Endocrinol. Lett. 2008, 29, 733–737.
[PubMed]
94. Rosenquist, T.A.; Einolf, H.J.; Dickman, K.G.; Wang, L.; Smith, A.; Grollman, A.P. Cytochrome P450 1A2
detoxicates aristolochic acid in the mouse. Drug Metab. Dispos. 2010, 38, 761–768. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 2144 17 of 19
95. Levová, K.; Mizerovská, M.; Kotrbová, V.; Šulc, M.; Henderson, C.J.; Wolf, C.R.; Philips, D.H.; Frei, E.;
Schmeiser, H.H.; Mareš, J.; et al. Role of cytochromes P450 1A1/2 in detoxication and activation of
carcinogenic aristolochic acid I: Studies with the hepatic NADPH:cytochrome P450 reductase null (HRN)
mouse model. Toxicol. Sci. 2011, 121, 43–56. [CrossRef] [PubMed]
96. Stiborová, M.; Bárta, F.; Levová, K.; Hodek, P.; Schmeiser, H.H.; Arlt, V.M.; Martínek, V. A mechanism of
O-demethylation of aristolochic acid I by cytochromes P450 and their contributions to this reaction in human
and rat livers: Experimental and theoretical approaches. Int. J. Mol. Sci. 2015, 16, 27561–27575. [CrossRef]
[PubMed]
97. Arlt, V.M.; Levova, K.; Barta, F.; Shi, Z.; Evans, J.D.; Frei, E.; Schmeiser, H.H.; Nebert, D.W.; Phillips, D.H.;
Stiborova, M. Role of P450 1A1 and P450 1A2 in bioactivation versus detoxication of the renal carcinogen
aristolochic acid I: Studies in Cyp1a1(−/−), Cyp1a2(−/−), and Cyp1a1/1a2(−/−) mice. Chem. Res. Toxicol.
2011, 24, 1710–1719. [CrossRef] [PubMed]
98. Dracˇínská, H.; Bárta, F.; Levová, K.; Hudecová, A.; Moserová, M.; Schmeiser, H.H.; Kopka, K.; Frei, E.;
Arlt, V.M.; Stiborová, M. Induction of cytochromes P450 1A1 and 1A2 suppresses formation of DNA adducts
by carcinogenic aristolochic acid I in rats in vivo. Toxicology 2016, 344, 7–8. [CrossRef] [PubMed]
99. Xue, X.; Xiao, Y.; Zhu, H.; Wang, H.; Liu, Y.; Xie, T.; Ren, J. Induction of P450 1A by 3-methylcholanthrene
protects mice from aristolochic acid-I-induced acute renal injury. Nephrol. Dial. Transplant. 2008, 23,
3074–3081. [CrossRef] [PubMed]
100. Xiao, Y.; Ge, M.; Xue, X.; Wang, H.; Wu, X.; Li, L.; Liu, L.; Qi, X.; Zhang, Y.; Li, Y.; et al. Detoxication role of
hepatic cytochrome P450s in the kidney toxicity induced by aristolochic acid. Kidney Int. 2008, 73, 1231–1239.
[CrossRef] [PubMed]
101. Martínek, V.; Bárta, F.; Hodek, P.; Frei, E.; Schmeiser, H.H.; Arlt, V.M.; Stiborová, M. Comparison of the
oxidation of carcinogenic aristolochic acid I and II by microsomal cytochromes P450 in vitro: Experimental
and theoretical approaches. Monatshefte Chem. 2017.
102. Stiborova, M.; Barta, F.; Dracinska, H.; Hudecova, A.; Hodek, P.; Balogova, M.; Mraz, J.; Duskova, S.;
Schmeiser, H.H.; Arlt, V.M. Treatment with a mixture of aristolochic acid I and II influences their genotoxicity
and expression of biotransformation enzymes in rats in vivo. Toxicol. Lett. 2016, 256, S96. [CrossRef]
103. Schmeiser, H.; Schoepe, K.B.; Wiessler, M. DNA adduct formation of aristolochic acid I and II in vitro and
in vivo. Carcinogenesis 1988, 9, 297–303. [CrossRef] [PubMed]
104. Shibutani, S.; Dong, H.; Suzuki, N.; Ueda, S.; Miller, F.; Grollman, A.P. Selective toxicity of aristolochic acids I
and II. Drug Metab. Dispos. 2007, 35, 1217–1222. [CrossRef] [PubMed]
105. Arlt, V.M.; Meinl, W.; Florian, S.; Nagy, E.; Barta, F.; Thomann, M.; Mrizova, I.; Krais, A.M.; Liu, M.;
Richards, M.; et al. Impact of genetic modulation of SULT1A enzymes on DNA adduct formation by
aristolochic acids and 3-nitrobenzanthrone. Arch. Toxicol. 2017, 91, 1957–1975. [CrossRef] [PubMed]
106. Stiborová, M.; Frei, E.; Wiessler, M.; Schmeiser, H.H. Human enzymes involved in the metabolic activation
of carcinogenic aristolochic acids: Evidence for reductive activation by cytochromes P450 1A1 and 1A2.
Chem. Res. Toxicol. 2001, 14, 1128–1137. [CrossRef] [PubMed]
107. Stiborová, M.; Hájek, M.; Frei, E.; Schmeiser, H.H. Carcinogenic and nephrotoxic alkaloids aristolochic
acids upon activation by NADPH:cytochrome P450 reductase form adducts found in DNA of patients with
Chinese herbs nephropathy. Gen. Physiol. Biophys. 2001, 20, 375–392. [PubMed]
108. Stiborová, M.; Frei, E.; Breuer, A.; Wiessler, M.; Schmeiser, H.H. Evidence for reductive activation of
carcinogenic aristolochic acids by prostaglandin H synthase—32P-postlabeling analysis of DNA adduct
formation. Mutat. Res. 2001, 493, 149–160. [CrossRef]
109. Stiborová, M.; Frei, E.; Sopko, B.; Wiessler, M.; Schmeiser, H.H. Carcinogenic aristolochic acids upon
activation by DT-diaphorase form adducts found in DNA of patients with Chinese herbs nephropathy.
Carcinogenesis 2002, 23, 617–625. [CrossRef] [PubMed]
110. Martínek, V.; Kubickova, B.; Arlt, V.M.; Frei, E.; Schmeiser, H.H.; Hudecˇek, J.; Stiborova, M. Comparison
of activation of aristolochic acid I and II with NADPH:quinone oxidoreductase, sulphotransferases and
N-acetyltransferases. Neuro Endocrinol. Lett. 2011, 32 (Suppl. S1), S57–S70.
111. Stiborová, M.; Hudecˇek, J.; Frei, E.; Schmeiser, H.H. Contribution of biotransformation enzymes to the
development of renal injury and urothelial cancer caused by aristolochic acid: Urgent questions, difficult
answers. Interdiscip. Toxicol. 2008, 1, 8–12. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 2144 18 of 19
112. Stiborová, M.; Frei, E.; Sopko, B.; Sopková, K.; Marková, V.; Lanˇková, M.; Kumstýrˇová, T.; Wiessler, M.;
Schmeiser, H.H. Human cytosolic enzymes involved in the metabolic activation of carcinogenic aristolochic
acid: Evidence for reductive activation by human NAD(P)H:quinone oxidoreductase. Carcinogenesis 2003,
24, 1695–1703. [CrossRef] [PubMed]
113. Chen, M.; Gong, L.; Qi, X.; Xing, G.; Luan, Y.; Wu, Y.; Xiao, Y.; Yao, J.; Li, Y.; Xue, X.; et al. Inhibition
of renal NQO1 activity by dicoumarol suppresses nitroreduction of aristolochic acid I and attenuates its
nephrotoxicity. Toxicol. Sci. 2011, 122, 288–296. [CrossRef] [PubMed]
114. Stiborová, M.; Frei, E.; Arlt, V.M.; Schmeiser, H.H. Knock-out and humanized mice as suitable tools to identify
enzymes metabolizing the human carcinogen aristolochic acid. Xenobiotica 2014, 44, 135–145. [CrossRef]
[PubMed]
115. Stiborová, M.; Frei, E.; Schmeiser, H.H.; Arlt, V.M.; Martínek, V. Mechanisms of enzyme-catalyzed reduction
of two carcinogenic nitro-aromatics, 3-nitrobenzanthrone and aristolochic acid I: Experimental and theoretical
approaches. Int. J. Mol. Sci. 2014, 15, 10271–10295. [CrossRef] [PubMed]
116. Stiborová, M.; Levová, K.; Bárta, F.; Šulc, M.; Frei, E.; Arlt, V.M.; Schmeiser, H.H. The influence of dicoumarol
on the bioactivation of the carcinogen aristolochic acid I in rats. Mutagenesis 2014, 29, 189–200. [CrossRef]
[PubMed]
117. Sidorenko, V.S.; Attaluri, S.; Zaitseva, I.; Iden, C.R.; Dickman, K.G.; Johnson, F.; Grollman, A.P. Bioactivation
of the human carcinogen aristolochic acid. Carcinogenesis 2014, 35, 1814–1822. [CrossRef] [PubMed]
118. Hashimoto, K.; Zaitseva, I.N.; Bonala, R.; Attaluri, S.; Ozga, K.; Iden, C.R.; Johnson, F.; Moriya, M.;
Grollman, A.P.; Sidorenko, V.S. Sulfotransferase-1A1-dependent bioactivation of aristolochic acid I and
N-hydroxyaristolactam I in human cells. Carcinogenesis 2016, 37, 647–655. [CrossRef] [PubMed]
119. Meinl, W.; Pabel, U.; Osterloh-Quiroz, M.; Hengstler, J.G.; Glatt, H. Human sulphotransferases are involved
in the activation of aristolochic acids and are expressed in renal target tissue. Int. J. Cancer 2006, 118,
1090–1097. [CrossRef] [PubMed]
120. Stiborová, M.; Frei, E.; Hodek, P.; Wiessler, M.; Schmeiser, H.H. Human hepatic and renal microsomes,
cytochromes P450 1A1/2, NADPH:CYP reductase and prostaglandin H synthase mediate the formation of
aristolochic acid DNA-adducts found in patients with urothelial cancer. Int. J. Cancer 2005, 113, 189–197.
[CrossRef] [PubMed]
121. Stiborová, M.; Sopko, B.; Hodek, P.; Frei, E.; Schmeiser, H.H.; Hudecˇek, J. The binding of aristolochic acid I to
the active site of human cytochromes P450 1A1 and 1A2 explains their potential to reductively activate this
human carcinogen. Cancer Lett. 2005, 229, 193–204. [CrossRef] [PubMed]
122. Milichovský, J.; Bárta, F.; Schmeiser, H.H.; Arlt, V.M.; Frei, E.; Stiborová, M.; Martínek, V. Active site
mutations as a suitable tool contributing to explain a mechanism of aristolochic acid I nitroreduction by
cytochromes P450 1A1, 1A2, and 1B1. Int. J. Mol. Sci. 2016, 7, 213. [CrossRef]
123. Jerabek, P.; Martinek, V.; Stiborova, M. Theoretical investigation of differences in nitroreduction of aristolochic
acid I by cytochromes P450 1A1, 1A2 and 1B1. Neuro Endocrinol. Lett. 2012, 33 (Suppl. S3), 25–32. [PubMed]
124. Guengerich, F.P. Common and uncommon cytochrome P450 reactions related to metabolism and chemical
toxicity. Chem. Res. Toxicol. 2001, 14, 611–650. [CrossRef] [PubMed]
125. Guengerich, F.P. Cytochrome P450 and chemical toxicology. Chem. Res. Toxicol. 2008, 21, 70–83. [CrossRef]
[PubMed]
126. Rendic, S.; DiCarlo, F.J. Human cytochrome P450 enzymes: A status report summarizing their reactions,
substrates, inducers, and inhibitors. Drug Metab. Rev. 1997, 29, 413–480. [CrossRef] [PubMed]
127. Atanasova, S.Y.; von Ahsen, N.; Toncheva, D.I.; Dimitrov, T.G.; Oellerich, M.; Amstrong, V.M. Genetic
polymorphism of cytochrome P450 among patients with Balkan endemic nephropathy (BEN). Clin. Biochem.
2005, 38, 223–228. [CrossRef] [PubMed]
128. Ross, D.; Kepa, J.K.; Winski, S.L.; Beall, H.D.; Anwar, A.; Siegel, D. NAD(P)H:quinone oxidoreductase 1
(NQO1): Chemoprotection, bioactivation, gene regulation and genetic polymorphisms. Chem. Biol. Interact.
2000, 129, 77–97. [CrossRef]
129. Ross, D. Quinone reductases multitasking in the metabolic world. Drug Metab. Rev. 2004, 36, 639–654.
[CrossRef] [PubMed]
130. Bárta, F.; Levová, K.; Frei, E.; Schmeiser, H.H.; Arlt, V.M.; Stiborová, M. The effect of aristolochic acid I on
NAD(P)H:quinone oxidoreductase expression in mice and rats—A comparative study. Mutat. Res. 2014, 768,
1–7. [CrossRef] [PubMed]
Int. J. Mol. Sci. 2017, 18, 2144 19 of 19
131. Toncheva, D.; Dimitrov, T.; Stojanova, S. Etiology of Balkan endemic nephropathy: A multifactorial disease?
Eur. J. Epidemiol. 1998, 14, 389–394. [CrossRef] [PubMed]
132. Toncheva, D.I.; von Ahsen, N.; Atanasova, S.Y.; Dimitrov, T.G.; Armstrong, V.M.; Oellerich, M. Identification
of NQO1 and GSTs genotype frequencies in Bulgarian patients with Balkan endemic nephropathy. J. Nephrol.
2004, 17, 384–389. [PubMed]
133. He, P.; Court, R.H.; Greenblatt, D.J.; Von Moltke, L.L. Genotype-phenotype associations of cytochrome P450
3A4 and 3A5 polymorphism with midazolam clearance in vivo. Clin. Pharmacol. Ther. 2005, 77, 373–387.
[CrossRef] [PubMed]
134. Stefanovic´, V.; Toncheva, D.; Atanasova, S.; Polenakovic´, M. Etiology of Balkan endemic nephropathy and
associated urothelial cancer. Am. J. Nephrol. 2006, 26, 1–11. [CrossRef] [PubMed]
135. Toncheva, D. Genetic studies in BEN and associated urothelial cancers. Coll. Antropol. 2006, 30 (Suppl. S1), 34.
136. Chen, B.; Bai, Y.; Sun, M.; Ni, X.; Yang, Y.; Yang, Y.; Zheng, S.; Xu, F.; Dai, S. Glutathione S-transferases T1
null genotype is associated with susceptibility to aristolochic acid nephropathy. Int. Urol. Nephrol. 2012, 44,
301–307. [CrossRef] [PubMed]
137. Wang, B.; Wang, J.; Huang, S.Q.; Su, H.H.; Zhou, S.F. Genetic polymorphism of the human cytochrome P450
2C9 gene and its clinical significance. Curr. Drug Metab. 2009, 10, 781–834. [CrossRef] [PubMed]
138. Reljic, Z.; Zlatovic, M.; Savic-Radojevic, A.; Pekmezovic, T.; Djukanovic, L.; Matic, M.; Pljesa-Ercegovac, M.;
Mimic-Oka, J.; Opsenica, D.; Simic, T. Is increased susceptibility to Balkan endemic nephropathy in
carriers of common GSTA1 (*A/*B) polymorphism linked with the catalytic role of GSTA1 in ochratoxin a
biotransformation? Serbian case control study and in silico analysis. Toxins 2014, 6, 2348–2362. [CrossRef]
[PubMed]
© 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
